Constant Therapeutics
May 23, 2021
Constant Therapeutics is a small, private, and clinical stage therapeutics company developing Mas receptor agonists for the treatment of COVID-19, CNS disorders, rare diseases, and other indications. It’s lead compound, TXA127, is a pharmaceutical formulation of the natural human peptide Angiotensin-(1-7) (Ang-(1-7)). Lead clinical programs include COVID-19, chronic stroke recovery, epidermolysis bullosa and cardiomyopathy associated with Duchenne Muscular Dystrophy.
Recent News
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
- Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
